Pathology has been generally unchanged for 150 years. The process involves taking a piece of tissue–such as from a biopsy–putting it on a glass slide and examining it under a microscope.
“It’s incredible how analog this space is,” David West, CEO, said. “It’s the last ‘-ology’ to go digital, so this is really in the first inning.”
Philadelphia-based Proscia, a provider of digital and computational pathology tools, secured a $23 million Series B round of funding that will be used to accelerate the adoption of digital pathology globally. Scale Venture Partners led the round and was joined by Hitachi Ventures. The new round brings the company’s total funding to $35 million since being founded in 2014, including a $10.3 million Series A in 2018, according to Crunchbase data.
The company’s latest capital infusion will go toward achieving scale, commercial product development, data and regulatory. The company will also grow its team by two or three times in the coming quarters.
